Aethlon Medical (NASDAQ:AEMD) Announces Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Aethlon Medical (NASDAQ:AEMD) announced its earnings results on Thursday. The medical equipment provider reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.27, Zacks reports. During the same period in the prior year, the business earned ($1.10) EPS.

Aethlon Medical Stock Performance

Shares of AEMD stock traded down $0.08 during mid-day trading on Friday, hitting $0.50. The company’s stock had a trading volume of 1,707,769 shares, compared to its average volume of 11,476,545. The company’s fifty day simple moving average is $0.78 and its 200-day simple moving average is $1.44. Aethlon Medical has a 52 week low of $0.37 and a 52 week high of $5.00. The company has a market cap of $1.31 million, a PE ratio of -0.10 and a beta of 1.60.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AEMD. HC Wainwright lowered their target price on Aethlon Medical from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, June 24th. StockNews.com began coverage on Aethlon Medical in a research report on Sunday, June 23rd. They issued a “sell” rating for the company.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.